Evidence map›Paper›PMID 42380487›Full record

Articlenpj drug discovery2025

Preclinical characterization of EGT710, an oral non-peptidomimetic reversible covalent SARS-CoV-2 main protease inhibitor.

Stephanie A Moquin, Suresh B Lakshminarayana, Kamal Kumar Balavenkatraman, Hilmar Schiller, Allison Claas, Barun Bhhatarai, Ioannis Loisios-Konstantinidis, Katarina Vulic, Chaitanya Kurhade, Birte K Kalveram and 25 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in npj drug discovery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors.

Stephanie A Moquin *Biomedical Research, Novartis, Emeryville, CA, USA. stephanie.moquin@novartis.com.
Suresh B Lakshminarayana *Biomedical Research, Novartis, Emeryville, CA, USA.
Kamal Kumar BalavenkatramanBiomedical Research, Novartis, Basel, Switzerland.
Hilmar SchillerBiomedical Research, Novartis, Basel, Switzerland.
Allison ClaasBiomedical Research, Cambridge, MA, USA.
Barun BhhataraiBiomedical Research, Cambridge, MA, USA.
Ioannis Loisios-KonstantinidisBiomedical Research, Novartis, Basel, Switzerland.
Katarina VulicDevelopment, Novartis, Cambridge, MA, USA.
Chaitanya KurhadeUniversity of Texas Medical Branch, Galveston, TX, USA.
Birte K KalveramUniversity of Texas Medical Branch, Galveston, TX, USA.
John Yun-Chung ChenUniversity of Texas Medical Branch, Galveston, TX, USA.
Jing ZouUniversity of Texas Medical Branch, Galveston, TX, USA.
Xuping XieUniversity of Texas Medical Branch, Galveston, TX, USA.
Laura TandeskeBiomedical Research, Novartis, Emeryville, CA, USA.
Dustin DovalaBiomedical Research, Novartis, Emeryville, CA, USA.
Elizabeth OrnelasBiomedical Research, Novartis, Emeryville, CA, USA.
Mark S KnappBiomedical Research, Novartis, Emeryville, CA, USA.
Daniel FullerBiomedical Research, Cambridge, MA, USA.
Zachary NguyenBiomedical Research, Cambridge, MA, USA.
David T BarkanBiomedical Research, Cambridge, MA, USA.
Lidiya BebrevskaBiomedical Research, Novartis, Basel, Switzerland.
S Kirk WrightBiomedical Research, Cambridge, MA, USA.
Scott A BusbyBiomedical Research, Cambridge, MA, USA.
Johanne BlaisBiomedical Research, Novartis, Emeryville, CA, USA.
Pei-Yong ShiUniversity of Texas Medical Branch, Galveston, TX, USA.
Suzanne GaudetBiomedical Research, Cambridge, MA, USA.
Renee BergeronBiomedical Research, Novartis, East Hanover, NJ, USA.
Hannah YuDevelopment, Novartis, Cambridge, MA, USA.
Julia ZackBiomedical Research, Novartis, East Hanover, NJ, USA.
Christopher SarkoBiomedical Research, Novartis, Emeryville, CA, USA.
Feng GuBiomedical Research, Novartis, Emeryville, CA, USA.
James E BradnerBiomedical Research, Cambridge, MA, USA.
John A TallaricoBiomedical Research, Cambridge, MA, USA.
Thierry T DiaganaBiomedical Research, Novartis, Emeryville, CA, USA.
Julien P N PapillonBiomedical Research, Cambridge, MA, USA.

Funding

Gates Foundation INV 033028
6 · The paper itself

Abstract

EGT710 is an orally bioavailable non-peptidomimetic reversible covalent coronavirus main protease (Mpro) inhibitor with low nM cellular activity against SARS-CoV-2. Twice daily dosing of 10 mg/kg of EGT710 decreased lung viral load in a mouse model of SARS-CoV-2 infection to below the limit of detection. Resistance selection resulted in the emergence of several Mpro mutations, with recombinant viruses containing L50F + E166A substitutions showing the largest shift in potency. Development of a viral kinetics model using viremia data from clinical trials, along with a human physiologically based pharmacokinetic model, predicted efficacy in humans with once daily oral doses of >360 mg. EGT710 displays favorable pharmacokinetic properties and an acceptable in vitro and in vivo safety profile, with human exposures at the recommended clinical dose of 600 mg predicted to be below the no adverse effect level in preclinical toxicology studies. Together, EGT710 has a promising preclinical profile and has completed a Phase I study.

Identifiers

PMID42380487
PMCPMC13267108

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.